Por: The Boston Globe Business May 24, 2023
The Food and Drug Administration is delaying by one month its long-awaited decision on whether to approve a gene therapy for a deadly inherited muscle-wasting disease that afflicts more than 10,000 boys and young men nationwide, according to the Cambridge biotech that developed the medicine.Sarepta Therapeutics said Wednesday that after discussions with the FDA, the agency has postponed until June 22 its deadline for deciding whether to give... + full article
ABC News USA Health June 23, 2023
WASHINGTON -- The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's ability to help boys with the inherited disease.The Food and Drug... + más
Bills' Nyheim Hines opens up about family members' struggles with muscular dystrophy, hopes to inspire people | Fox News
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids | WPLG Local 10
WPLG Local 10 USA Health June 23, 2023
WASHINGTON – The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's ability to help boys with the inherited disease.The Food and Drug... + más
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids | ABC News
Time USA Health June 23, 2023
For genetic conditions like Duchenne muscular dystrophy, there is little doctors can do to slow or treat the condition other than trying to manage symptoms, since only addressing the genetic changes responsible can help halt the disease. Earlier today (June 22), the U.S. Food... + más
The Boston Globe USA Business June 22, 2023
The Food and Drug Administration on Thursday approved the first gene therapy for Duchenne muscular dystrophy, a $3.2 million one-time treatment from a Cambridge biotech for a deadly inherited neuromuscular disorder that afflicts more than 10,000 boys and young men in the US.But... + más
FDA advisers recommend accelerated approval of a Sarepta gene therapy | The Boston Globe
The Boston Globe USA Business May 23, 2023
Regulators are to decide within days whether to clear a Cambridge biotech’s gene therapy for a deadly muscle-wasting disease that afflicts more than 10,000 boys and young men nationwide, even though questions remain about whether the treatment is safe and effective.The... + más
Gene therapy has made some recent progress—is it enough? | Ars Technica
The Boston Globe USA Business May 13, 2023
An panel of advisers Friday recommended that the Food and Drug Administration speed up approving a Duchenne muscular dystrophy treatment developed by Cambridge biotech Sarepta Therapeutics, despite questions about its clinical benefit and safety.By an 8 to 6 vote, the FDA... + más
Under pressure from patients, FDA faces tough choices on experimental gene therapy | The Boston Globe
FDA delays decision on Sarepta’s controversial gene therapy for muscular dystrophy | The Boston Globe
Fox News USA Sports February 16, 2023
Nyheim Hines had a challenging 2022 season as he was traded from the Colts to the after he spent the first four full seasons of his NFL career in Indianapolis. But for the veteran running back, life on the field can pale in comparison to what’s happening off it.Hines recently... + más
Bills' Nyheim Hines believes NFL will listen to players about field conditions, shares insight on Josh Allen | Fox News
AFC-best Bills trade Zack Moss, pick to Colts for RB Nyheim Hines | ABC News
About iurex | Privacy Policy | Disclaimer |